Assistant professor
- b.leeneman@erasmusmc.nl
Erasmus School of Health Policy & Management
Assistant professor | Health Technology Assessment (HTA)
- leeneman@eshpm.eur.nl
More information
Work
- Rianne L. Seefat, Sonja B. Vliek, Vincent M.T. de Jong, Sara Balduzzi, Ingrid A. Mandjes, Valesca P. Retèl, Inge Eekhout, Marjolein Delfos, Margaret Schot, Marjo J. Holtkamp, Mandy M. van Rosmalen, Brenda Leeneman, Hedwig Blommestein, Alwin D.R. Huitema, Efraim H. Rosenberg, Petra M. Nederlof, Terry W.S. Chan, Anna van Rhenen, Marielle J. Wondergem, Nicolaas P.M. Schaap, Tjeerd J.F. Snijders, Marjolein W.M. Van der Poel, Wouter J. Plattel, Erik van Werkhoven, Harm van Tinteren, Marjolein L. Smidt, Jelle Wesseling, Jos Jonkers, Sven Rottenberg, Marie Jeanne T.F.D. Vrancken Peeters, Carlijn Voermans, John H. Maduro, Judith R. Kroep, Carolien P. Schroder, Evelien J.M. Kuip, Anthony Gonçalves, Janine Nuver, A. N.Machteld Wymenga, Rhodé M. Bijlsma, Elsken van der Wall, Inge R.H.M. Konings, Vivianne C.G. Tjan-Heijnen, Mojca Jongen-Lavrencic, Agnes Jager & Sabine C. Linn (2026) - Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology, 27 (7), 795-807 - doi: 10.1016/S1470-2045(26)00131-2 - [link]
- Diego Larrotta-Castillo, Yi Hsuan Chen, Luuk van der Hoek, Bram Ramaekers, Brenda Leeneman, Carin A. Uyl-De Groot, Johannes A. Langendijk & Hedwig M. Blommestein (2026) - Post-radiotherapy health utility and symptom trends in patients with non-metastatic head and neck cancer - Radiotherapy and Oncology, 219 - doi: 10.1016/j.radonc.2026.111473 - [link]
- Julia A. van den Broek, Antonius W. Schurink, Brenda Leeneman, Tessa Brabander, Astrid A.M. van der Veldt, Cornelius Verhoef & Dirk J. Grünhagen (2026) - Preoperative ultrasound before sentinel lymph node biopsy in melanoma in the era of neoadjuvant treatment: a systematic review and meta-analysis of diagnostic performance and cost analysis - EClinicalMedicine, 92 - doi: 10.1016/j.eclinm.2026.103770 - [link]
- Brenda Leeneman, Hedwig M. Blommestein, Diana M.J. Delnoij & Maureen P.M.H. Rutten-Van Mölken (2026) - Evaluating international collaboration on horizon scanning for pharmaceuticals: Developing Key Performance Indicators for the International Horizon Scanning Initiative - International Journal of Technology Assessment in Health Care, 42 (1) - doi: 10.1017/S0266462325103358 - [link]
- Saskia de Groot, Hedwig M. Blommestein, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Pieter H.M. van Baal (2025) - Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma - Medical Decision Making, 45 (3), 302-317 - doi: 10.1177/0272989X251319338 - [link]
- Hedwig M. Blommestein, Saskia de Groot, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Margreet G. Franken (2025) - Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model - European Journal of Cancer, 218 - doi: 10.1016/j.ejca.2024.115071 - [link]
- N. S.H. Xander, B. Leeneman, A. M.C. Dingemans, W. E. Fiets, W. K. de Jong, N. E.M. Uyl, A. N.M. Wymenga, A. K.L. Reyners & C. A. Uyl-de Groot (2024) - Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not? - European Journal of Cancer, 209 - doi: 10.1016/j.ejca.2024.114262 - [link]
- Olivier J. van Not, Alfons J.M. van den Eertwegh, Hilde Jalving, Manja Bloem, John B. Haanen, Rozemarijn S. van Rijn, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan Willem de Groot J W B, Geke A.P. Hospers, Ellen Kapiteijn, Brenda Leeneman, Piersma D, Marion Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil G, Michel W.J.M. Wouters, Willeke A.M. Blokx & Karijn P.M. Suijkerbuijk (2024) - Long-Term Survival in Patients With Advanced Melanoma - JAMA network open, 7 (8) - doi: 10.1001/jamanetworkopen.2024.26641 - [link]
- Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A. N.Machteld Wymenga, An K.L. Reyners & Carin A. Uyl-de Groot (2024) - Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness - European Journal of Cancer, 202 - doi: 10.1016/j.ejca.2024.114002 - [link]
- Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2026
- Course Code
- GW4560M
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year Level
- master
- Year
- 2026
- Course Code
- GW4585M
